Jaydess

Levonorgestrel, the active ingredient in Jaydess, is a progestin presented as a 13.5 mg intrauterine system (IUS) for intrauterine use. It prevents pregnancy and can be used to manage heavy menstrual bleeding in women of reproductive age. The device releases levonorgestrel locally, providing long‑acting reversible contraception for up to three years while also reducing menstrual blood loss.

GNH USA supplies Jaydess as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levonorgestrel in Jaydess is a progestin‑based intrauterine system used for hormonal contraception and menstrual management.

- Contraception (prevention of pregnancy): Provides long‑acting reversible birth control by inhibiting ovulation and thickening cervical mucus. - Heavy menstrual bleeding: Reduces menstrual blood loss and stabilizes the endometrial lining, improving bleeding symptoms.

Levonorgestrel released from the intrauterine system may be associated with a range of adverse reactions.

Common Side Effects: - Irregular vaginal bleeding or spotting - Amenorrhea (absence of periods) - Pelvic or abdominal cramping - Breast tenderness

Serious or Rare Side Effects: - Uterine perforation - Device expulsion - Pelvic infection, including tubo‑ovarian abscess

When considering Jaydess, several precautionary measures should be observed to ensure safe use.

- Pregnancy screening: confirm the patient is not pregnant before insertion. - Infection assessment: treat any active pelvic infection prior to placement. - Uterine evaluation: avoid use in known uterine anomalies or fibroids that distort the cavity. - Bleeding counseling: inform patients about possible changes in menstrual bleeding patterns. - Contraindication review: do not use in women with known or suspected breast cancer, liver disease, or thromboembolic disorders. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Levonorgestrel released from Jaydess can interact with certain medicines that affect hormone metabolism.

Major Interactions (Avoid): - Rifampin, carbamazepine, phenytoin: enzyme inducers that may lower levonorgestrel levels, reducing contraceptive effectiveness. - Antiretroviral agents such as efavirenz: may decrease hormone concentrations and compromise efficacy.

Moderate Interactions (Monitor Closely): - Ketoconazole and other azole antifungals: can increase levonorgestrel levels, potentially enhancing side effects. - St. John’s wort: may modestly reduce hormone effectiveness. - Combined estrogen‑containing contraceptives: additive progestogenic effects may increase risk of hormonal side effects.